* suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of covid-19 * treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, tumor necrosis factor (tnf) inhibitors and anti-il-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. note: immunomodulators (topical or inhaled) for asthma and atopic dermatitis, and corticosteroids (any route of administration) such as dexamethasone are permitted. * history of hypersensitivity to canakinumab or to biologic drugs * neutrophil count \<1000/mm3 * pregnant or nursing (lactating) women * participation in another study with investigational drug within the 30 days preceding and during the present study-

* suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of covid-19 * treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, tumor necrosis factor (tnf) inhibitors and anti-il-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. note: immunomodulators (topical or inhaled) for asthma and atopic dermatitis, and corticosteroids (any route of administration) such as dexamethasone are permitted. * history of hypersensitivity to canakinumab or to biologic drugs * neutrophil count \<1000/mm3 * pregnant or nursing (lactating) women * participation in another study with investigational drug within the 30 days preceding and during the present study-

- suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of covid-19 - treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, tumor necrosis factor (tnf) inhibitors and anti-il-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. note: immunomodulators (topical or inhaled) for asthma and atopic dermatitis, and corticosteroids (any route of administration) such as dexamethasone are permitted. - history of hypersensitivity to canakinumab or to biologic drugs - neutrophil count <1000/mm3 - pregnant or nursing (lactating) women - participation in another study with investigational drug within the 30 days preceding and during the present study-

- suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of covid-19 - treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, tumor necrosis factor (tnf) inhibitors and anti-il-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. note: immunomodulators (topical or inhaled) for asthma and atopic dermatitis, and corticosteroids (any route of administration) such as dexamethasone are permitted. - history of hypersensitivity to canakinumab or to biologic drugs - neutrophil count <1000/mm3 - pregnant or nursing (lactating) women - participation in another study with investigational drug within the 30 days preceding and during the present study-